214 related articles for article (PubMed ID: 23921229)
1. Design, synthesis and evaluation of a potent substrate analog inhibitor identified by scanning Ala/Phe mutagenesis, mimicking substrate co-evolution, against multidrug-resistant HIV-1 protease.
Yedidi RS; Muhuhi JM; Liu Z; Bencze KZ; Koupparis K; O'Connor CE; Kovari IA; Spaller MR; Kovari LC
Biochem Biophys Res Commun; 2013 Sep; 438(4):703-8. PubMed ID: 23921229
[TBL] [Abstract][Full Text] [Related]
2. A multi-drug resistant HIV-1 protease is resistant to the dimerization inhibitory activity of TLF-PafF.
Yedidi RS; Proteasa G; Martin PD; Liu Z; Vickrey JF; Kovari IA; Kovari LC
J Mol Graph Model; 2014 Sep; 53():105-111. PubMed ID: 25108107
[TBL] [Abstract][Full Text] [Related]
3. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
Logsdon BC; Vickrey JF; Martin P; Proteasa G; Koepke JI; Terlecky SR; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
J Virol; 2004 Mar; 78(6):3123-32. PubMed ID: 14990731
[TBL] [Abstract][Full Text] [Related]
5. Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease.
Liu Z; Wang Y; Brunzelle J; Kovari IA; Kovari LC
Protein J; 2011 Mar; 30(3):173-83. PubMed ID: 21394574
[TBL] [Abstract][Full Text] [Related]
6. P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease.
Yedidi RS; Liu Z; Kovari IA; Woster PM; Kovari LC
J Mol Graph Model; 2014 Feb; 47():18-24. PubMed ID: 24291501
[TBL] [Abstract][Full Text] [Related]
7. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
[TBL] [Abstract][Full Text] [Related]
8. Systematic profiling of substrate binding response to multidrug-resistant mutations in HIV-1 protease: Implication for combating drug resistance.
Lv Y; Li J; Fang J; Jiao X; Yan L; Shan B
J Mol Graph Model; 2017 Jun; 74():83-88. PubMed ID: 28371730
[TBL] [Abstract][Full Text] [Related]
9. Novel Protease Inhibitors Containing C-5-Modified
Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
[TBL] [Abstract][Full Text] [Related]
10. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
11. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
[TBL] [Abstract][Full Text] [Related]
12. Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
Ghosh AK; Rao KV; Nyalapatla PR; Osswald HL; Martyr CD; Aoki M; Hayashi H; Agniswamy J; Wang YF; Bulut H; Das D; Weber IT; Mitsuya H
J Med Chem; 2017 May; 60(10):4267-4278. PubMed ID: 28418652
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of multidrug-resistant HIV-1 protease in complex with two potent anti-malarial compounds.
Yedidi RS; Liu Z; Wang Y; Brunzelle JS; Kovari IA; Woster PM; Kovari LC; Gupta D
Biochem Biophys Res Commun; 2012 May; 421(3):413-7. PubMed ID: 22469467
[TBL] [Abstract][Full Text] [Related]
14. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design.
Velazquez-Campoy A; Muzammil S; Ohtaka H; Schön A; Vega S; Freire E
Curr Drug Targets Infect Disord; 2003 Dec; 3(4):311-28. PubMed ID: 14754432
[TBL] [Abstract][Full Text] [Related]
15. The higher barrier of darunavir and tipranavir resistance for HIV-1 protease.
Wang Y; Liu Z; Brunzelle JS; Kovari IA; Dewdney TG; Reiter SJ; Kovari LC
Biochem Biophys Res Commun; 2011 Sep; 412(4):737-42. PubMed ID: 21871444
[TBL] [Abstract][Full Text] [Related]
16. Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants.
Ghosh AK; Rao KV; Nyalapatla PR; Kovela S; Brindisi M; Osswald HL; Sekhara Reddy B; Agniswamy J; Wang YF; Aoki M; Hattori SI; Weber IT; Mitsuya H
ChemMedChem; 2018 Apr; 13(8):803-815. PubMed ID: 29437300
[TBL] [Abstract][Full Text] [Related]
17. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM
Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363
[TBL] [Abstract][Full Text] [Related]
18. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.
Kempf DJ
Methods Enzymol; 1994; 241():334-54. PubMed ID: 7854187
[No Abstract] [Full Text] [Related]
19. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
Koh Y; Nakata H; Maeda K; Ogata H; Bilcer G; Devasamudram T; Kincaid JF; Boross P; Wang YF; Tie Y; Volarath P; Gaddis L; Harrison RW; Weber IT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2003 Oct; 47(10):3123-9. PubMed ID: 14506019
[TBL] [Abstract][Full Text] [Related]
20. GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.
Grantz Šašková K; Kozíšek M; Stray K; de Jong D; Rezáová P; Brynda J; van Maarseveen NM; Nijhuis M; Cihlár T; Konvalinka J
J Virol; 2014 Mar; 88(6):3586-90. PubMed ID: 24371077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
